Invention Grant
- Patent Title: Tricyclic rho kinase inhibitors
-
Application No.: US16461029Application Date: 2017-11-29
-
Publication No.: US10654860B2Publication Date: 2020-05-19
- Inventor: Wu Yang , Peter W. Glunz , Rajeev S. Bhide , Kamalraj Thiyagarajan
- Applicant: BRISTOL-MYERS SQUIBB COMPANY
- Applicant Address: US NJ Princeton
- Assignee: Bristol-Myers Squibb Company
- Current Assignee: Bristol-Myers Squibb Company
- Current Assignee Address: US NJ Princeton
- Agent Hong Liu
- International Application: PCT/US2017/063554 WO 20171129
- International Announcement: WO2018/102325 WO 20180607
- Main IPC: C07D487/10
- IPC: C07D487/10 ; C07D403/10 ; C07D471/04 ; C07D491/052 ; C07D491/147 ; C07D231/54 ; C07D487/04 ; C07D403/04 ; A61K31/436

Abstract:
The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same.
Public/Granted literature
- US20190276466A1 TRICYCLIC RHO KINASE INHIBITORS Public/Granted day:2019-09-12
Information query